These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Honeybee products and COVID-19.pdf (1.32 MB)
In Silico Screening of Potent Bioactive Compounds from Honey Bee Products Against COVID-19 Target Enzymes
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 11.07.2020 and posted on 15.07.2020by Moataz A. Shaldam, Galal Yahya, Nashwa H. Mohamed, Mohamed M. Abdel-Daim, Yahya Al Naggar
From the early days of the COVID-19 pandemic, side by side to immense investigates to design specific drugs
or to develop a potential vaccine for the novel coronavirus. Myriads of FDA
approved drugs are massively repurposed for COVID-19 treatment based on
molecular docking of selected protein targets that play vital for the
replication cycle of the virus. Honey bee products are well known of their
nutritional values and medicinal effects. Antimicrobial activity of bee
products and natural honey have been documented in several clinical studies and
was considered a good alternative for antiviral medications to treat some viral
infections. Bee products contain bioactive compounds in the form of a
collection of phenolic acids, flavonoids and terpenes of natural origin. We revealed
by molecular docking the profound binding affinity of 14 selected phenolics and
terpenes present in honey and propolis (bees glue) against the main protease (Mpro) and RNA dependent RNA polymerase (RdRp) enzymes
of the novel 2019-nCoV coronavirus. Of these compounds, p-coumaric acid, ellagic acid, kaemferol and
the strongest interaction with the 2019-nCoV target enzymes, and they may be
considered as an effective 2019-nCoV inhibitors.